Randomized double-blind trial of injectable heptaminol for controlling spontaneous or bromocriptine-induced orthostatic hypotension in parkinsonians.
Identifieur interne : 005A77 ( Main/Merge ); précédent : 005A76; suivant : 005A78Randomized double-blind trial of injectable heptaminol for controlling spontaneous or bromocriptine-induced orthostatic hypotension in parkinsonians.
Auteurs : D. Milon [France] ; H. Allain ; J M Reymann ; G. Morel ; O. Sabouraud ; J. Van Den DriesscheSource :
- Fundamental & clinical pharmacology [ 0767-3981 ] ; 1990.
English descriptors
- KwdEn :
- Blood Pressure (drug effects), Bromocriptine (adverse effects), Double-Blind Method, Female, Heart Rate (drug effects), Heptaminol (adverse effects), Heptaminol (therapeutic use), Humans, Hypotension, Orthostatic (chemically induced), Hypotension, Orthostatic (drug therapy), Injections, Intravenous, Male, Middle Aged, Parkinson Disease (drug therapy), Renin (blood).
- MESH :
- chemical , adverse effects : Bromocriptine, Heptaminol.
- chemical , blood : Renin.
- chemically induced : Hypotension, Orthostatic.
- drug effects : Blood Pressure, Heart Rate.
- drug therapy : Hypotension, Orthostatic, Parkinson Disease.
- chemical , therapeutic use : Heptaminol.
- Double-Blind Method, Female, Humans, Injections, Intravenous, Male, Middle Aged.
Abstract
Heptaminol is a molecule with experimental cardiovascular analeptic properties. In this double-blind vs placebo trial, the potency, so far unproven, of the injectable form of a 626 mg dose of heptaminol chlorhydrate on spontaneous or induced orthostatic hypotension (OH), was assessed. Nineteen patients were included in the study: 7 displayed spontaneous OH, and in the other 12 OH was induced by bromocriptine, as monitored 103 min/after an oral intake of 6.6 mg on average. Neither spontaneous nor induced OH were recorded in 32% of the Parkinsonian population registered, with no obvious distinctive characteristics. Potency tilt-trials, performed 15, 30 and 45 min after parenteral administration of heptaminol, revealed a significant and expressive potency of the molecule on the systolic blood pressure after 15 min (P less than 0.05). Clinical and biological tolerance was excellent. Low plasma renin activity and the absence of response to orthostatism indicated, in this population of Parkinsonian extrapyramidal syndromes, a loss in positive tonus likely to be of sympathetic origin. The anti-hypotensive action of heptaminol does not seem to be related to any renal or even sympathetic interaction.
PubMed: 2096108
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 001827
- to stream PubMed, to step Curation: 001786
- to stream PubMed, to step Checkpoint: 001786
- to stream Ncbi, to step Merge: 000C38
- to stream Ncbi, to step Curation: 000C38
- to stream Ncbi, to step Checkpoint: 000C38
Links to Exploration step
pubmed:2096108Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Randomized double-blind trial of injectable heptaminol for controlling spontaneous or bromocriptine-induced orthostatic hypotension in parkinsonians.</title><author><name sortKey="Milon, D" sort="Milon, D" uniqKey="Milon D" first="D" last="Milon">D. Milon</name><affiliation wicri:level="1"><nlm:affiliation>Laboratoire de Pharmacologie Expérimentale et Clinique, CHR de Rennes, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Laboratoire de Pharmacologie Expérimentale et Clinique, CHR de Rennes</wicri:regionArea><wicri:noRegion>CHR de Rennes</wicri:noRegion><wicri:noRegion>CHR de Rennes</wicri:noRegion></affiliation></author><author><name sortKey="Allain, H" sort="Allain, H" uniqKey="Allain H" first="H" last="Allain">H. Allain</name></author><author><name sortKey="Reymann, J M" sort="Reymann, J M" uniqKey="Reymann J" first="J M" last="Reymann">J M Reymann</name></author><author><name sortKey="Morel, G" sort="Morel, G" uniqKey="Morel G" first="G" last="Morel">G. Morel</name></author><author><name sortKey="Sabouraud, O" sort="Sabouraud, O" uniqKey="Sabouraud O" first="O" last="Sabouraud">O. Sabouraud</name></author><author><name sortKey="Van Den Driessche, J" sort="Van Den Driessche, J" uniqKey="Van Den Driessche J" first="J" last="Van Den Driessche">J. Van Den Driessche</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="1990">1990</date><idno type="RBID">pubmed:2096108</idno><idno type="pmid">2096108</idno><idno type="wicri:Area/PubMed/Corpus">001827</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001827</idno><idno type="wicri:Area/PubMed/Curation">001786</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001786</idno><idno type="wicri:Area/PubMed/Checkpoint">001786</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001786</idno><idno type="wicri:Area/Ncbi/Merge">000C38</idno><idno type="wicri:Area/Ncbi/Curation">000C38</idno><idno type="wicri:Area/Ncbi/Checkpoint">000C38</idno><idno type="wicri:doubleKey">0767-3981:1990:Milon D:randomized:double:blind</idno><idno type="wicri:Area/Main/Merge">005A77</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Randomized double-blind trial of injectable heptaminol for controlling spontaneous or bromocriptine-induced orthostatic hypotension in parkinsonians.</title><author><name sortKey="Milon, D" sort="Milon, D" uniqKey="Milon D" first="D" last="Milon">D. Milon</name><affiliation wicri:level="1"><nlm:affiliation>Laboratoire de Pharmacologie Expérimentale et Clinique, CHR de Rennes, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Laboratoire de Pharmacologie Expérimentale et Clinique, CHR de Rennes</wicri:regionArea><wicri:noRegion>CHR de Rennes</wicri:noRegion><wicri:noRegion>CHR de Rennes</wicri:noRegion></affiliation></author><author><name sortKey="Allain, H" sort="Allain, H" uniqKey="Allain H" first="H" last="Allain">H. Allain</name></author><author><name sortKey="Reymann, J M" sort="Reymann, J M" uniqKey="Reymann J" first="J M" last="Reymann">J M Reymann</name></author><author><name sortKey="Morel, G" sort="Morel, G" uniqKey="Morel G" first="G" last="Morel">G. Morel</name></author><author><name sortKey="Sabouraud, O" sort="Sabouraud, O" uniqKey="Sabouraud O" first="O" last="Sabouraud">O. Sabouraud</name></author><author><name sortKey="Van Den Driessche, J" sort="Van Den Driessche, J" uniqKey="Van Den Driessche J" first="J" last="Van Den Driessche">J. Van Den Driessche</name></author></analytic><series><title level="j">Fundamental & clinical pharmacology</title><idno type="ISSN">0767-3981</idno><imprint><date when="1990" type="published">1990</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Blood Pressure (drug effects)</term><term>Bromocriptine (adverse effects)</term><term>Double-Blind Method</term><term>Female</term><term>Heart Rate (drug effects)</term><term>Heptaminol (adverse effects)</term><term>Heptaminol (therapeutic use)</term><term>Humans</term><term>Hypotension, Orthostatic (chemically induced)</term><term>Hypotension, Orthostatic (drug therapy)</term><term>Injections, Intravenous</term><term>Male</term><term>Middle Aged</term><term>Parkinson Disease (drug therapy)</term><term>Renin (blood)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Bromocriptine</term><term>Heptaminol</term></keywords><keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Renin</term></keywords><keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Hypotension, Orthostatic</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Blood Pressure</term><term>Heart Rate</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Hypotension, Orthostatic</term><term>Parkinson Disease</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Heptaminol</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Double-Blind Method</term><term>Female</term><term>Humans</term><term>Injections, Intravenous</term><term>Male</term><term>Middle Aged</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Heptaminol is a molecule with experimental cardiovascular analeptic properties. In this double-blind vs placebo trial, the potency, so far unproven, of the injectable form of a 626 mg dose of heptaminol chlorhydrate on spontaneous or induced orthostatic hypotension (OH), was assessed. Nineteen patients were included in the study: 7 displayed spontaneous OH, and in the other 12 OH was induced by bromocriptine, as monitored 103 min/after an oral intake of 6.6 mg on average. Neither spontaneous nor induced OH were recorded in 32% of the Parkinsonian population registered, with no obvious distinctive characteristics. Potency tilt-trials, performed 15, 30 and 45 min after parenteral administration of heptaminol, revealed a significant and expressive potency of the molecule on the systolic blood pressure after 15 min (P less than 0.05). Clinical and biological tolerance was excellent. Low plasma renin activity and the absence of response to orthostatism indicated, in this population of Parkinsonian extrapyramidal syndromes, a loss in positive tonus likely to be of sympathetic origin. The anti-hypotensive action of heptaminol does not seem to be related to any renal or even sympathetic interaction.</div></front></TEI></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/Main/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 005A77 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Merge/biblio.hfd -nk 005A77 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonFranceV1
|flux= Main
|étape= Merge
|type= RBID
|clé= pubmed:2096108
|texte= Randomized double-blind trial of injectable heptaminol for controlling spontaneous or bromocriptine-induced orthostatic hypotension in parkinsonians.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Merge/RBID.i -Sk "pubmed:2096108" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Merge/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonFranceV1
| This area was generated with Dilib version V0.6.29. |  |